Drug intelligence / Profile preview

DWRX6007

Development stage: Preclinical
Lead developer: Daewoong Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

DWRX6007 is a preclinical-stage, biomarker-based small molecule synthetic lethality drug being developed by Daewoong Therapeutics for the treatment of advanced solid cancers. The therapeutic strategy of DWRX6007 relies on synthetic lethality, a phenomenon where the co-occurrence of two genetic events (such as a specific tumor biomarker/mutation and drug-induced inhibition of a complementary pathway) leads to selective cancer cell death while sparing healthy tissues. The specific gene target and biomarker for DWRX6007 remain undisclosed by the developer.

Beyond the preview

Go deeper on DWRX6007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWRX6007.

Explore the full profile